Title

Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation
Assessment of the Evolution of Macular Pigment Density in Two Distinct Populations, Before and After Supplementation With Nutrof Total Versus Dietary Supplement Without Lutein and Zeaxanthin, Using the Macular Pigment Module of Visucam 200 or Visucam 500 (Zeiss).
  • Phase

    N/A
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    zeaxanthin xanthophyll ...
  • Study Participants

    200
•Purpose: Age-related Macular Degeneration ( AMD) is the leading cause of blindness and visual impairment in industrialized countries. The macular pigment, composed of carotenoid derivatives (lutein and zeaxanthin), may play an important role in the occurrence of AMD. An increase in macular pigment following dietary supplementation with lutein and zeaxanthin could allow early treatment with such supplements in subjects with a high risk of AMD, and encourage them to change their eating habits.

•Primary outcome:

Comparative analysis of the density and evolution of the density of macular pigment:

In patients without any retinal pathology who underwent cataract surgery 1 month previously

In the non-exudative eye of patients with exudative AMD in one eye by analyzing the density and evolution of the density of macular pigment in the non-exudative eye

Secondary outcomes:

Analysis of changes in macular pigment density after taking food supplements (Nutrof Total versus comparator):

Time taken to reach the maximum plateau of macular pigment density (no increase in density between 2 measurements)

Time taken to return to the baseline macular pigment density after cessation of supplementation

Study design :

Pilot study -Prospective, randomised, double-masked, comparative, multicenter.
Study Started
Sep 30
2011
Primary Completion
Dec 31
2014
Study Completion
Jan 31
2015
Last Update
Jun 24
2015
Estimate

Dietary Supplement Nutrof Total

Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).

Dietary Supplement food supplement without Lutein and Zeaxanthin

food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.

B: patients with wet AMD in one eye. Active Comparator

group B: patients with wet AMD in one eye. In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin.

A :patients without retinal pathology Active Comparator

group A :patients without retinal pathology who underwent cataract surgery 1 month previously. In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin.

Criteria

Inclusion criteria:

Both genders (male or female), ≥ 55 years of age.
Patients without any retinal pathology who underwent cataract surgery 1 month previously Or
Patients with neovascular AMD (Age-related macular Degeneration) in one eye.
Patients who gave their written consent

Exclusion Criteria:

Exclusion criteria related to the study:

Intolerance to the tested product
Change in fundus image
Patients already taking Nutrof Total or similar supplements containing Lutein and Zeaxanthin
Allergy to mydriatics

Exclusion criteria for ophthalmologic reasons:

o Ocular diseases or conditions whose presence might interfere with the measurement of optical density of macular pigment (e.g. cataract, diabetic retinopathy, optic atrophy, myopia> -6.5 Diopters)

Exclusion criteria for systemic reasons:

o Medical or surgical history, disorder or disease (e.g. severe organic disease, acute or chronic: liver disease, endocrine, neoplastic, hematologic, infectious diseases, severe psychiatric disorder, significant cardiovascular abnormalities, etc...) and / or aggravating factors or structural defect, considered as being inconsistent with the study by the investigator.

Exclusion criteria for general reasons:

Inability of the patient to understand the study procedures and to give informed consent.
Ward of court
Patient not covered by the social security scheme
Pregnancy
No Results Posted